Skip to content

Studying the effect of nimodipin, progesterone and magnesium sulfate in the treatment of severe head injury

Comparison study the effect of nimodipine, magnesium sulfate and progesterone in the treatment of severe head injury with conventional therapy on reducing mortality rate

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201210229534N2
Enrollment
124
Registered
2014-01-18
Start date
2012-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head Trauma. Other and unspecified injuries of head

Interventions

Intervention 1: progesterone based on a mg per kg(s) initially and then the same amount every 12 hours for 5 days Intervention group. Intervention 2: nimodipine 60 milli grams every 4 hours for 21 day
Treatment - Drugs
progesterone based on a mg per kg(s) initially and then the same amount every 12 hours for 5 days Intervention group
nimodipine 60 milli grams every 4 hours for 21 days Intervention group
5 grams of magnesium sulfate initially and than 2 and a half grams daily for 5 days Intervention group

Sponsors

Hamadan Univesity of Medical Science,Hamedan University of Medical Sciences-vice chancellor for rese
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: All patients with head injury and with Glascow Coma Scale lower than 8 who will refers to Emergency ward of Besat Hospital in the 1392 year. Exclusion criteria: Pregnant woman; Any type of brain surgery; Instability from surgical aspect; Using estrogen and progesterone in the last 30 days; Brain death; Systolic blood pressure below 90; Patients with kidney problems

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Patient's death. Timepoint: During 6 Month. Method of measurement: Follow the patient.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSepideh Sohrabi

Hamadan University of Medical Science

Habibi67.arman@yahoo.com+98 81 1264 0020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 21, 2026